Japan medical device reimbursements will generally go down slightly in 2022, but some new technologies with clear benefits will not. Discussions on reimbursement revisions in 2022 are being held by the Insurance Medical Material Special Subcommittee of the Central Social Insurance Medical... Read More
With software-driven therapeutic interventions for patient treatments known as digital therapeutics (DTx) beginning to make a mark in the world of patient care, the government of South Korea is beginning to lay the groundwork for the entrance of the technologies into its... Read More
Low insurance reimbursement rates in Taiwan are discouraging the development of innovative pharmaceutical products, according to a study by Fitch Solutions. Because essential healthcare for all residents of the island nation is covered by a single public system, and hospitals negotiate with... Read More
A major state-sanctioned political party in China made up primarily of medical and health science researchers is calling for making rare disease treatments eligible for government health insurance reimbursement. The public plea this spring by the Chinese Peasants and Workers Democratic Party... Read More
In recognition of the growing popularity and importance of mobile software applications that diagnose, track or treat disease, Japan is considering making the use of such apps eligible for reimbursement by its government health insurance system. The question of how and whether... Read More
Seeking to better control costs of hospital stays, China is taking steps to adopt a payment classification system batching cases that are clinically similar and are expected to use the same levels of hospital resources into groups for the purposes of determining... Read More
Basic health insurance plans in China will begin this year to cover the cost of most drugs used to treat rare diseases, according to a National Healthcare Security Administration statement released in December. Under the plan, rare disease drugs that are proven... Read More
Twenty-nine new drugs produced by Chinese pharmaceutical companies were added to the new National Drug Reimbursement List (NRDL) in January, squeezing out foreign competitors, whose offerings were deemed by review panels to be exorbitantly priced. The success of such a relatively large... Read More
The long-simmering question of when and how Japan will implement a proposed plan to evaluate and revise drug prices annually, instead of every two years, may finally be resolved next year. That is when a survey being conducted by the Ministry of... Read More
Accelerating efforts to make the island of Hainan into a center for medical innovation—and medical tourism — local authorities have approved an insurance plan for the island that will cover foreign drugs and treatments not yet approved on the mainland. The government-backed... Read More